WO2002010193A1 - Lipid-peptide conjugates for treatment of cancer - Google Patents
Lipid-peptide conjugates for treatment of cancer Download PDFInfo
- Publication number
- WO2002010193A1 WO2002010193A1 PCT/US2000/020876 US0020876W WO0210193A1 WO 2002010193 A1 WO2002010193 A1 WO 2002010193A1 US 0020876 W US0020876 W US 0020876W WO 0210193 A1 WO0210193 A1 WO 0210193A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- leu
- tyr
- pro
- met
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer.
Description
NOVEL PEPTIDES FOR TREATMENT OF CANCER
FIELD OF INVENTION This invention relates to novel antiproliferative and anti secrectory peptides that are inhibitory to vasoactive intestinal peptide receptor and are useful in the treatment of cancer. The invention particularly relates to the synthesis of lipid-peptide conjugates containing fatty acids of different sizes, which inhibits the binding of VIP to its receptors. The invention encompasses methods for generation of these peptides, composition containing these peptides and the pharmacological applications of these peptides especially in the treatment and prevention of cancer. BACKGROUND OF THE INVENTION
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide, which was first isolated from the porcine intestine (Said, S. I. and Mutt, V. , Science, 169, 1217-1218, 1970.) VIP acts as growth factor and plays dominant autocrine and paracrine role in the sustained proliferation of cancer cells. (Said, S.L, Peptides, 5, 143-150, 1984.) Gozes et al. have shown that VIP can serve as autocrine growth factor in lung tumors. (Gozes et al. Biomed. Res. 13 (suppl.2) 37, 1992).
The peptide sequence Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys (SEQ ID NO: 1) is reported to be receptor binding inhibitor of vasoactive intestinal peptide (Said, & Mutt, Ann. N.Y. Acad. Sci., 1, 527, 1988). The role this octapeptide as VIP receptor binding inhibitor has been described in the U.S Patent 5,217,953. In our U.S. Patent Application 08/727,679 we have described the anti cancer role of this VIP binding receptor inhibitor in combination with other neuropeptide analogs. In another U.S. Patent Application 09/248382 we have described the novel analogs of this VIP receptor binding inhibitor incorporating dialkylated amino acids.
Keeping in view that lipophilization of bioactive peptides improves their stability, bioavailability and the ability to permeate biomembranes (Dasgupta, P. et al.; 1999, Pharmaceutical Res. 16, 1047-1053; Gozes, I. et al., 1996, Proc. Natl. Acad. Sci. USA, 93, 427-432.), in the present invention we have synthesized lipid conjugates of the peptide sequence Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys (SEQ ID NO: 1) using fatty acids of different sizes, C2- C16 carbon atoms, at the N-terrninal site of the peptide. Throughout the application the following abbreviation are used with
the following meanings:
BOP : Benzotriazole- 1 -yl-oxy-tris-(dimethylamino)- phosphonium hexofluorophospate
PyBOP : Benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium hexofluorophospate
HBTU: O-Benzotriazole-N,N,N' ,N' -tetramethyl-uronium- hexofluoro-phosphate
TBTU: 2-(lH-Benzotriazole-lyl)- 1 , 1 ,3,3,-tetramethyluronium tetrafluoroborate HOBt: 1-Hydroxy Benzotriazole
DCC: Dicyclohexyl carbodiimide
DIPCD: Diisopropyl carbodiimide
DIEA: Diisopropyl ethylamine
DMAP: 4-Dimethylamino pyridine DMF: Dimethyl formamide
DCM: Dichloromethane
NMP: N-Methyl-2-pyrrolidinone
TFA: Trifluoroacetic acid
Throughout the specification and claims, the amino acids residues are designated by their standard abbreviations. Amino acids denote L-configuration unless otherwise indicated by D or DL appearing before the symbol and separated from it by hyphen.
Throughout the specification and claims, the amino acids residues are designated by their standard abbreviations. Amino acids denote L-configuration unless otherwise indicated by D or DL appearing before the symbol and separated from it by hyphen.
SUMMARY OF THE INVENTION The present invention relates to peptides of the following general formula X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein,
X is acetyl or straight, branched, or cyclic al anoyl group of from 3 -
16 carbon atoms.
Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptides.
BRIEF DESCRIPTION OF THE FIGURE Figure 1 shows the anti-cancer activity of the peptide DT-B1 on PCT xenograft.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to peptides of the following general formula X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein,
X is acetyl or straight, branched, or cyclic alkanoyl group of from 3 - 16 carbon atoms.
Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptides.
The preferred alkanoyl groups are acetyl, n-butanoyl, n-hexanoyl, n-octanoyl, lauroyl, myristoyl, palmitoyl, isohexanoyl, cyclohexanoyl, cyclopentylcarbonyl, n-heptanoyl, n-decanoyl, n-undecanoyl, and 3,7-dimethyloctanoyl. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Representative salts and esters include following: acetate, ascorbate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, camsylate, carbonate, citrate, dihydrochloride, methanesulfonate, ethanesulfonate, p-toluenesulfonate, cyclohexylsulfamate, quinate, edetate, edisylate, estolate, esylate, fumarate, gluconate, glutamate, glycerophophates, hydrobromide, hydrochloride, hydroxy- naphthoate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, mucate, napsylate, nitrate, n-methylglucamine, oleate, oxalate, pahnoates, pamoate (embonate), palmitate, pantothenate, perchlorates, phosphate/diphosphate, polygalacturonate, salicylates, stearate, succinates, sulfate, sulfamate, subacetate, succinate, tannate, tartrate, tosylate, trifluoroacetate and valerate.
Other salts include Ca, Li, Mg, Na, and K salts; salts of amino acids
such as lysine or arginine; guanidine, diethanolamine or choline; ammonium, substituted ammonium salts or aluminum salts.
The salts are prepared by conventional methods.
The preferred lipo-peptide analogs are:
Acetyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (DT-A1) (SEQ ID NO:
2) n-Butanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (DT-B1) (SEQ ID
NO: 3) n-Octanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (DT-01) (SEQ ID NO: 4) Myristoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH(DT-Ml) (SEQ ID NO: 5) Palmitoyl- Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (DT-P1) (SEQ ID
NO: 6) The novel compounds of the present invention have important pharmacological applications. They are potent anti-neoplastic agents and thereby possess therapeutic potential in a number of human cancers.
The lipopeptides in the present invention have been generated by using solid phase techniques or by a combination of solution phase procedures and solid phase techniques or by fragment condensation. The methods for the chemical synthesis of polypeptides are well known in the art (Stewart and Young, 1969 Solid
Phase Synthesis, W.H. Freeman Co.).
In a preferred embodiment of the present invention the peptides were synthesized using the Fmoc strategy, on a semi automatic peptide synthesizer (CS Bio, Model 536), using optimum side chain protection. The peptides were assembled from C-terminus to N-terminus. Peptides amidated at the carboxy-terminus were synthesized using the Rink Amide resin. The loading of the first Fmoc protected amino acid was achieved via an amide bond formation with the solid support, mediated by Diisopropylcarbodiimide (DIPCDI) and HOBt. Substitution levels for automated synthesis were preferably between 0.2 and 0.6 mmole amino acid per gram resin. The steps involved in the synthesis of the peptide analogs employed the following protocol:
TABLE I
STEP REAGENT MIX TIME NO. OF (MIN) CYCLES
1. Methylene chloride 1 2
2. Dimethyl formarnide 1 1
3. 20 % Piperidine in 1 1 Dimethyl formarnide
4. 20 % Piperidine in 29 1 Dimethyl formarnide
5. Dimethyl formarnide 1 3
6. Isopropanol 1 2
7. Methylene chloride 1 2
8. Amino Acid Variable 1
9. Dimethyl formarnide 1 2
10. Stop or Return for next cycle
In a particularly preferred embodiment of the present invention the following chemical moieties were used to protect reactive side chains of the peptides during the synthesis procedure:
The N-terminal amino group was protected by 9-fluorenylmethoxy- carbonyl (Fmoc) group. The hydroxyl groups of Threonine and Tyrosine were preferably protected by t-butyl group (tBu). Leu, Met and Pro were used unprotected.
In a preferred embodiment of the invention, 2-8 equivalents of Fmoc protected amino acid per resin nitrogen equivalent were used. The activating reagents used for coupling amino acids to the resin, in solid phase peptide synthesis, are well known in the art. These include DCC, DIPCDI, DIEA, BOP, PyBOP, HBTU, TBTU, and HOBt. Preferably, DCC or DIPCDI / HOBt or HBTU/HOBt and DIEA were used as activating reagents in the coupling reactions. The protected amino acids were either activated in situ or added in the form of preactivated esters known in the art such as N-hydroxy succinamide esters, pentafluorophenyl esters etc. The coupling reaction was carried out in DMF, DCM or NMP or a mixture of these solvents and was monitored by Kaiser test [Kaiser et al., Anal. Biochem., 34,
595-598 (1970)]. In case of a positive Kaiser test, the appropriate amino acid was re-coupled using freshly prepared activated reagents.
After the assembly of the peptide analog was completed, the amino-terminal Fmoc group was removed using steps 1-6 of the above protocol and then the peptide-resin was washed with methanol and dried. The analogs were then deprotected and cleaved from the resin support by treatment with trifluoroacetic acid, crystalline phenol, ethanedithiol, thioanisole and de-ionized water for 1.5 to 5 hours at room temperature. The crude peptide was obtained by precipitation with cold dry ether, filtered, dissolved, and lyophilized. The resulting crude peptide was purified by preperative high performance liquid chromatography (HPLC) using a LiChrOCART® C18 (250. Times. 10) reverse phase column (Merck, Darmstadt, Germany) on a Preparative HPLC system (Shimadzu Corporation, Japan) using a gradient of 0.1 % TFA in acetonitrile and water. The eluted fractions were reanalyzed on Analytical HPLC system (Shimadzu Corporation, Japan) using a C18 LiChrospher®, WP-300 (300 X • 4) reverse-phase column. Acetonitrile was evaporated and the fractions were lyophilized to obtain the pure peptide. The identity of each peptide was confirmed by electron-spray mass spectroscopy.
An analog of the present invention can be made by exclusively solid phase techniques, by partial solid phase/solution phase techniques and/or fragment condensation. Preferred, semi-automated, stepwise solid phase methods for synthesis of peptides of the invention are provided in the examples discussed in the subsequent section of this document.
The present invention will be further described in detail with reference to the following examples, as will be appreciated by a person skilled in the art is merely illustrative* and should not be construed as limiting. Various other modifications of the invention will be possible without departing from the spirit and scope of the present invention.
Synthesis of peptides First loading on Wang Resin
A typical preparation of the Fmoc-Lys-Wang Resin was carried out using 1.0 g of 4-Hydroxymethylphenoxy Resin 1% DVB cross-linked resin (0.7
mM/g) (100-200 mesh), procured from Advanced Chemtech, Louisville, KY, U.S.A. Swelling of the resin was typically carried out in dichloromethane measuring to volumes 10-40ml/g resin. The resin was allowed to swell in methylene chloride (2 X 25 ml, for 10 min.). It was washed once in dimethylformamide (DMF) for 1 min. All solvents in the protocol were added in 20 ml portions per cycle. For loading of the first amino acid on hydroxyl group of the resin, the first amino acid, was weighed in three to six fold excess, along with a similar fold excess of HOBt, in the amino acid vessel of the peptide synthesizer. These were dissolved in dimethylformamide (A.C.S. grade) (J.T.Baker,, New Jersey, U.S.A.) and activated with DIPCDI and 4-dimethyl amino pyridine (DMAP)just prior to the addition to the resin in the reaction vessel of the peptide synthesizer. The coupling reaction was carried out for a period ranging from 6 hours. The loading of the amino acid on the resin was confirmed by the weight gain of the resin. The loading efficiency was ascertained by the increase of weight of the resin after the addition of the amino acid.
EXAMPLE 1 Synthesis of Acetyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lvs-OH (DT-Al
(SEQ ID NO: 2) The synthesis of peptide DT-A1 was initiated by using resin loaded with Fmoc-Lys-OH as prepared above on lg scale. It was subjected to stepwise deprotection and coupling steps as in steps 1-10 of the synthesis cycle. In each coupling reaction, a four-fold excess of appropriate Fmoc amino acid, DIPCDI and HOBt were used. The average coupling time for each amino acids was between 2-5 hrs. On completion of synthesis and removal of the N-terminal Fmoc protecting group (steps 1-6 of the synthesis cycle), the peptideresin was washed twice with methanol. It was further coupled with acetic anhydride in DMF using DIPCDI and HOBt as coupling agents. This was subjected to cleavage in a cleavage mixture consisting of trifluoroacetic acid and scavengers, crystalline phenol, thioanisole, ethanedithol and water for a period of 1-4 hours at room temperature with continuous stirring. The peptide was precipitated using cold dry ether to obtain the crude peptide. The crude peptide was purified on a C preparative reverse phase HPLC column (250 X 10) on a gradient system comprising acetonitrile and water in
0.1% TFA as described previously, in the art. The prominent peaks were collected and lyophilized, reanalyzed on analytical HPLC and subjected to mass spectrometry. There was a good agreement between the observed molecular weight and calculated molecular weight (calculated mass = ~ 1070; observed mass = 1071.1). The pure peptide was then used for bioassays.
EXAMPLE 2 Synthesis of n-Butanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lvs-OH (DT-Bll
SEQ ID NO: 3 The above peptide sequence was synthesized on resin in a similar way as described in Example 1 except n-butyric anhydride is used in place of acetic anhydride. The final purified peptide was further analyzed by mass spectroscopy. The calculated mass and observed mass was in good agreement (calculated mass = ~ 1098, observed mass = 1099.3).
EXAMPLE 3 Synthesis of n-Octanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lvs-OH fPT-Ol
(SEQ ID NO: 4) The above peptide sequence was synthesized on resin in a similar way as described in Example 1 except octanoic acid is used in place of acetic anhydride. The final purified peptide was further analyzed by mass spectroscopy. The calculated mass is ~ 1154 and observed mass is 1155.2.
EXAMPLE 4 Synthesis of Myristoyl -Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lvs-OH fDT-MD
The above peptide sequence was synthesized on resin in a similar way as described in Example 1 except myristic acid is used in place of acetic anhydride. The final purified peptide was further analyzed by mass spectroscopy (calculated mass = ~ 1238, observed mass = 1239.6).
EXAMPLE 5 Synthesis of Palmitoyl- Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lvs-OH fDT-Pn rSEO ID NO: 6)
The above peptide sequence was synthesized on resin in a similar way as described in Example 1 except palmitic acid is used in place of acetic
anhydride. The final purified peptide was further analyzed by mass spectroscopy (calculated mass = ~ 1262, observed mass = 1263.4).
EXAMPLE 6 The cytotoxic effect of Lipo peptide analogs, DT-A1 (SEQ ID NO: 2), DT-Bl (SEQ ID NO: 3), DT-Ol (SEQ ID NO: 4), DT-Ml (SEQ ID NO: 5) and DT-P1 (SEQ ID NO: 6) was studied by MTT assay which is based on the principle of uptake of MTT [3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide], a tetrazolium salt by the metabolically active cells where it is metabolized by active mitochondria into a blue colored formazan product which can be read spectrophoto- metrically. Briefly, tumor cells PTC (primary colon) KB (Oral squamous), U87MG (Glioblastoma), HBL100 (Breast), HeP2 (Laryngeal), ECV304 (Endothelial), PA-1 (Ovary) and LI 32 (Lung) were incubated with the peptide analogs for 48 hours at 37°C in a 96-well culture plate, followed by the addition of 100 μg MTT and further incubation of 1 hour. The formazan crystals formed inside the cells were dissolved with a detergent comprising 10% Sodium dodecyl sulfate and 0.01 N HCl and optical density read on a multiscan ELISA reader. The optical density was directly proportional to the number of proliferating and metabolically active cells. Percent cytotoxicity of peptide analogs is shown in the following Tables.
DT-A1
EXAMPLE 7 In vivo activity of Lipo-peptide analogs
The antitumor activity of DT-Bl (SEQ ID NO: 3) was studied in human colon adenocarcinoma (PTC) xenografts in nude mice. PTC tumor xenografts were grown in Balb/c a thymic mice by subcutaneous inoculation of a single cell suspension of PTC cells (15 X 106 cells/100 μL). The tumor bearing animals were divided into 2 groups of three animals each including one group
comprising untreated control animals. Treatment with DT-Bl was initiated when the average tumor volumes, as measured using a vernier caliper, were between 1.3 cm3. Solutions of DT-Bl was prepared at a concentration of 126 μg/ml and intravenously administered to the assigned group of tumor bearing animals at a dose of 12.6 μg/100 μL twice a day so that the total dose of 25.2μg/day was administered to each animal. The treatment was continued for a period of 14 days.
The antitumor activity of the compounds was monitored by measuring tumor volumes every fourth day using the formula W*W*L*0.4 (W = smaller diameter, L = larger diameter). The percentage inhibition of tumor growth was calculated using the formula (1- tumor volume-treated/tumor volume-control) * 100. Figure 1 shows the tumor kinetics till day 20 in the treated and untreated animals. DT-Bl showed a significant antitumor activity on PTC xenografts. The percentage inhibition of tumor growth caused by DT-Bl as compared to controls on day 20 was 95.85%. All publications referenced are incorporated by reference herein, including the amino acid sequences listed in each publication. All the compounds disclosed and referred to in the publications mentioned above are incorporated by reference herein, including those compounds disclosed and referred to in articles cited by the 10 publications mentioned.
Claims
1. A peptide derivative of the formula X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein, X is acetyl or straight, branched, or cyclic alkanoyl group from 3-16 carbon atoms and
Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptide.
2. A peptide derivative of claim 1, wherein the alkanoyl groups is selected from acetyl, n-butanoyl, n-hexanoyl, n-octanoyl, lauroyl, myristoyl, pahnitoyl, isohexanoyl, cyclohexanoyl, cyclopentylcarbonyl, n-heptanoyl, n- decanoyl, n-undecanoyl, or 3,7-dimethyloctanoyl.
3. A peptide derivative of claim 1, wherein X is Acetyl and the peptide is:
Acetyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof.
4. A peptide derivative of claim 1, wherein X is butanoyl and the peptide is: n-Butanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO: 3) or a pharmaceutically acceptable salt thereof.
5. A peptide derivative of claim 1, wherein X is n-octanoyl and the peptide is: n-Octanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO: 4) or a pharmaceutically acceptable salt thereof
6. A peptide derivative of claim 1, wherein X is Myristoyl and the peptide is:
Myristoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO: 5) or a pharmaceutically acceptable salt thereof.
7. A peptide derivative of claim 1, wherein X is Pahnitoyl and the peptide is: Palmitoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO: 6)] or a pharmaceutically acceptable salt thereof.
8. A composition comprising an effective amount of a polypeptide according to claim 1, and a pharmaceutically acceptable carrier.
9. A method of treatment of cancer in mammals which comprises the administration of an effective amount of polypeptide according to claim 1, alone or in combination with other polypeptides or anticancer compounds.
10. A solid phase synthesis process for preparation of a peptide analog of the formula:
X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein X is acetyl or straight, branched, or cyclic alkanoyl group from 3 - 16 carbon atoms and Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutical acceptable salt of the peptide which comprises sequentially loading protected amino acids in sequential cycles to the amino terminus of a solid phase resin, coupling the amino acids to assemble a peptide-resin assembly, removing the protecting groups and cleaving the peptide from the resin to obtain a peptide.
11. The process as claimed in claim 10, wherein the coupling is carried out in the presence of activating agents selected from the group consisting of DCC,
DIPCDI, DIEA, BOP, PyBOP, HBTU, TBTU, and HOBt.
12. The process as claimed in claim 10, wherein the coupling was carried out in the presence of a solvent selected from the group consisting of DMF, DCM, NMP or any mixtures thereof.
13. A process as claimed in claim 10, wherein said crude peptide is cleaved from said peptide-resin assembly by treatment with trifluoroacetic acid, crystalline phenol, ethanedithiol, thioanisole and water for 1.5 to 5 hours at room temperature.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2000265054A AU2000265054A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
| EP00952334A EP1409519A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
| PCT/US2000/020876 WO2002010193A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
| CA002405728A CA2405728A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/020876 WO2002010193A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002010193A1 true WO2002010193A1 (en) | 2002-02-07 |
Family
ID=21741642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2000/020876 WO2002010193A1 (en) | 2000-07-31 | 2000-07-31 | Lipid-peptide conjugates for treatment of cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1409519A1 (en) |
| AU (1) | AU2000265054A1 (en) |
| CA (1) | CA2405728A1 (en) |
| WO (1) | WO2002010193A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1633380A2 (en) * | 2003-06-19 | 2006-03-15 | Yeda Research & Development Company, Ltd. | Antimicrobial and anticancer lipopeptides |
| WO2017132728A1 (en) | 2016-02-01 | 2017-08-10 | University Of Canberra | Proteinaceous compounds and uses therefor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0354992A2 (en) * | 1988-07-08 | 1990-02-21 | Yeda Research And Development Company Limited | Conjugates of VIP and active fragments thereof with hydrophobic moieties and topical compositions for use in the treatment of male impotence |
| US5217953A (en) * | 1990-11-30 | 1993-06-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Vasoactive intestinal peptide antagonist |
| US5565424A (en) * | 1994-02-07 | 1996-10-15 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Superactive VIP antagonists |
| WO2000023096A2 (en) * | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
-
2000
- 2000-07-31 EP EP00952334A patent/EP1409519A1/en not_active Withdrawn
- 2000-07-31 CA CA002405728A patent/CA2405728A1/en not_active Abandoned
- 2000-07-31 WO PCT/US2000/020876 patent/WO2002010193A1/en active Application Filing
- 2000-07-31 AU AU2000265054A patent/AU2000265054A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0354992A2 (en) * | 1988-07-08 | 1990-02-21 | Yeda Research And Development Company Limited | Conjugates of VIP and active fragments thereof with hydrophobic moieties and topical compositions for use in the treatment of male impotence |
| US5217953A (en) * | 1990-11-30 | 1993-06-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Vasoactive intestinal peptide antagonist |
| US5565424A (en) * | 1994-02-07 | 1996-10-15 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Superactive VIP antagonists |
| WO2000023096A2 (en) * | 1998-10-16 | 2000-04-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Combination therapy with vip antagonist |
Non-Patent Citations (1)
| Title |
|---|
| See also references of EP1409519A1 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1633380A2 (en) * | 2003-06-19 | 2006-03-15 | Yeda Research & Development Company, Ltd. | Antimicrobial and anticancer lipopeptides |
| EP1633380A4 (en) * | 2003-06-19 | 2010-08-11 | Yeda Res & Dev | Antimicrobial and anticancer lipopeptides |
| US8445636B2 (en) | 2003-06-19 | 2013-05-21 | Yeda Research & Development Co. Ltd. | Antimicrobial and anticancer lipopeptides |
| WO2017132728A1 (en) | 2016-02-01 | 2017-08-10 | University Of Canberra | Proteinaceous compounds and uses therefor |
| JP2019506167A (en) * | 2016-02-01 | 2019-03-07 | ユニバーシティ・オブ・キャンベラＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｎｂｅｒｒａ | Proteinaceous compounds and their use |
| JP7341451B2 (en) | 2016-02-01 | 2023-09-11 | エピアクシス セラピューティクス プロプライアタリー リミティド | Proteinaceous compounds and their uses |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2000265054A1 (en) | 2002-02-13 |
| EP1409519A1 (en) | 2004-04-21 |
| CA2405728A1 (en) | 2002-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI94350B (en) | Process for producing peptides with T-cell helper activity | |
| JP2744910B2 (en) | Peptide derivatives | |
| CN104017062A (en) | Acylated GLP-1 compounds | |
| HUT50487A (en) | Process for production of peptides | |
| US4438029A (en) | Synthetic peptides | |
| LV10108B (en) | Inhibitors of cells proliferation, pharmaceutical composition, process of producing of compounds, methods of inhibition of cellular proliferation | |
| US7060678B2 (en) | Peptides comprising furanoid sugar amino acids for the treatment of cancer | |
| JPH06321988A (en) | New straight-chain peptide | |
| US6828304B1 (en) | Peptides for treatment of cancer | |
| US5079231A (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them | |
| US6316414B1 (en) | Somatostatin analogs for the treatment of cancer | |
| CA2405704C (en) | Bombesin analogs for treatment of cancer | |
| WO2002010193A1 (en) | Lipid-peptide conjugates for treatment of cancer | |
| DK164875B (en) | GONADOLIBERIN DERIVATIVES AND THEIR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS OR METAL COMPLEXES, A PROCEDURE FOR PREPARING THEM AND A PHARMACEUTICAL PREPARATION CONTAINING THESE | |
| HU205771B (en) | Process for producing irreversible peptide ligands for bombesin receptors and process for producing pharmaceutical compositions comprising such peptides as active ingredient | |
| JPH0631314B2 (en) | Novel gonadobereline derivative | |
| CA2405724C (en) | Substance p analogs for the treatment of cancer | |
| US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
| EP1198478B1 (en) | Somatostatin analogs and their use for the treatment of cancer | |
| Sakura et al. | Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity | |
| SÜLI‐VARGHA et al. | Synthesis of N‐(2‐chloroethyl)‐N‐nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments | |
| US6989371B1 (en) | Bombesin analogs for treatment of cancer | |
| JP3109835B2 (en) | Peptides for inhibiting pepsin release | |
| JP2672677B2 (en) | LHRH homolog | |
| EP1348714B1 (en) | Polypeptide useful as anti-allergic/antiasthmatic, methods for the preparation thereof and pharmaceutical compositions containing such polypeptide and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2405728 Country of ref document: CA |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2000952334 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 2000952334 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |